ClinicalTrials.gg
RecruitingNCT07424287Updated Jul 20, 2026

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

A Phase 3 interventional study of SHR-1501 for Injection and BCG for Injection in NMIBC, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
12th of 47
236 · median 114
Started
2026
with 9 others
Phase 3
12 of 50
8 open now
Primary completion
2030-06
later than 41 of 43 live
Registered
40th of 50
by date
Lead sponsor
2 of 50
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 12th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 41 of the 43 other live ones, and was the 40th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive papillary-only non-muscle-invasive bladder cancer (NMIBC).

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged at least 18 years, gender is not limited;
  2. (ECOG) performance status of ≤ 2;
  3. Histologic confirmation of high-risk non-muscle invasive bladder cancer (high-grade Ta and/or any T1, no carcinoma in situ); BCG-unresponsive;
  4. Cystoscopy within 6 weeks before the randomization shows that the lesion has been completely removed; for T1 stage lesions, pathological results must show the presence of bladder muscle tissue;
  5. Not suitable for or unwilling to undergo radical cystectomy;
  6. Sufficient hematology and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Previous histopathological diagnosis was muscle-invasive, locally advanced or urothelial carcinoma (T2 or T3 or T4 or N+ or M+);
  2. Received surgery such as TURBT or radiotherapy for bladder lesions within 2 weeks before the randomization; Major surgery was performed within 28 days before randomization;
  3. Those who have previously received the following treatments and have not experienced disease recurrence or progression before enrolment: a) Intravesical infusion of cytotoxic chemotherapy or other drugs (such as oncolytic viruses), etc; b) ; c) Other investigatory drugs for the treatment of NMIBC;
  4. Those who have previously received immunostimulant therapy;
  5. Upper urinary tract tumor detected by CTU or MRU during screening period, urethral prostate tumor detected by cystoscopy, or other concomitant malignant tumors within 5 years before the first administration;
  6. Previous medical history or examination suggests active tuberculosis within 1 year prior to the randomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    SHR-1501 + BCG Group

    SHR-1501, Bacillus Calmette Guerin (BCG).

    Drug: SHR-1501 for Injection · Drug: BCG for Injection

  • Active comparator
    Investigator-selected Chemotherapy Group

    Epirubicin or Pirarubicin or Gemcitabine or Hydroxycamptothecin or Mitomycin.

    Drug: Epirubicin Hydrochloride for Injection · Drug: Pirarubicin Hydrochloride for Injection · Drug: Gemcitabine Hydrochloride for Injection · Drug: Hydroxycamptothecin for Injection · Drug: Mitomycin for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) assessed by Blinded Independent Central Review (BICR)

    Disease free survival is defined as the time from randomization to date of DFS event assessed by BICR.

    Time frame: Up to approximately 5 years.

Secondary outcomes

  1. Disease-Free Survival (DFS) assessed by investigator

    Disease-free survival (DFS) is defined as the time from randomization to date of DFS event assessed by investigator.

    Time frame: Up to approximately 5 years.

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to date of death from any cause.

    Time frame: Up to approximately 5 years.

  3. Number of adverse events (AEs) as assessed by CTCAE v6.0.

    Time frame: Up to approximately 5 years.

  4. Number of serious adverse events (SAEs) as assessed by CTCAE v6.0.

    Time frame: Up to approximately 5 years.

07

Study locations

2 of 2 sites recruiting
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
    Recruiting
    • Zhisong He · Contactwyj7074@sohu.com · +86-010-83572600
    • Zhisong He · Principal investigator
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
    • Wei Xue · Contacturoxuewei@163.com · +86-021-58752345
    • Wei Xue · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jun 2030, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07424287
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Jul 13, 2026
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jul 20, 2026

Study contacts

Wenliang Wang
Contact
wenliang.wang@hengrui.com
+86-0518-82342973
Qi Zhang
Contact
qi.zhang@hengrui.com
+86-021-60453139

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efserakefusp alfa

Start the discussion